S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68

Allogene Therapeutics (ALLO) Stock Forecast, Price & News

-0.07 (-0.93%)
(As of 05/20/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
1.44 million shs
Average Volume
2.35 million shs
Market Capitalization
$1.07 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive ALLO News and Ratings via Email

Sign-up to receive the latest news and ratings for Allogene Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Allogene Therapeutics logo

About Allogene Therapeutics

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.


See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$38.49 million
Book Value
$5.96 per share


Net Income
$-257.01 million
Net Margins
Pretax Margin




Free Float
Market Cap
$1.07 billion
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.60 out of 5 stars

Medical Sector

89th out of 1,416 stocks

Biological Products, Except Diagnostic Industry

11th out of 210 stocks

Analyst Opinion: 4.4Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.0 5 -4 -3 -2 -1 -

Allogene Therapeutics (NASDAQ:ALLO) Frequently Asked Questions

Is Allogene Therapeutics a buy right now?

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Allogene Therapeutics in the last twelve months. There are currently 2 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Allogene Therapeutics stock.
View analyst ratings for Allogene Therapeutics
or view top-rated stocks.

When is Allogene Therapeutics' next earnings date?

Allogene Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for Allogene Therapeutics

How were Allogene Therapeutics' earnings last quarter?

Allogene Therapeutics, Inc. (NASDAQ:ALLO) posted its earnings results on Wednesday, May, 4th. The company reported ($0.56) EPS for the quarter, topping analysts' consensus estimates of ($0.58) by $0.02. Allogene Therapeutics had a negative net margin of 148,214.64% and a negative trailing twelve-month return on equity of 32.28%. During the same period in the prior year, the firm posted ($0.25) earnings per share.
View Allogene Therapeutics' earnings history

What price target have analysts set for ALLO?

13 brokers have issued 1 year price objectives for Allogene Therapeutics' shares. Their forecasts range from $12.00 to $53.00. On average, they anticipate Allogene Therapeutics' share price to reach $30.00 in the next twelve months. This suggests a possible upside of 301.1% from the stock's current price.
View analysts' price targets for Allogene Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Allogene Therapeutics' key executives?
Allogene Therapeutics' management team includes the following people:
  • Dr. Arie S. Belldegrun F.A.C.S., FACS, M.D., Co-Founder & Exec. Chairman (Age 73, Pay $845.19k)
  • Dr. David D. Chang M.D., Ph.D., Co-Founder, Pres, CEO & Director (Age 62, Pay $1.26M)
  • Mr. Joshua A. Kazam, Co-Founder & Director (Age 45, Pay $390k)
  • Dr. Eric Thomas Schmidt Ph.D., Chief Financial Officer (Age 52, Pay $660k)
  • Dr. Alison Moore Ph.D., Chief Technical Officer (Age 54, Pay $660k)
  • Mr. Veer Bhavnagri, Gen. Counsel & Compliance Officer (Age 39, Pay $646.88k) (LinkedIn Profile)
  • Dr. Rafael G. Amado, Chief Medical Officer and Exec. VP of R&D (Age 58, Pay $840k) (LinkedIn Profile)
  • Ms. Barbra Sasu, Chief Scientific Officer
  • Ms. Christine Cassiano, Chief Communications Officer
  • Mr. David M. Tanen J.D., Sec. (Age 51)
What is David Chang's approval rating as Allogene Therapeutics' CEO?

2 employees have rated Allogene Therapeutics CEO David Chang on Glassdoor.com. David Chang has an approval rating of 100% among Allogene Therapeutics' employees. This puts David Chang in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Allogene Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allogene Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Pfizer (PFE), Teladoc Health (TDOC), AbbVie (ABBV), Alibaba Group (BABA), Bristol-Myers Squibb (BMY) and CRISPR Therapeutics (CRSP).

When did Allogene Therapeutics IPO?

(ALLO) raised $272 million in an IPO on Thursday, October 11th 2018. The company issued 16,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Jefferies acted as the underwriters for the IPO.

What is Allogene Therapeutics' stock symbol?

Allogene Therapeutics trades on the NASDAQ under the ticker symbol "ALLO."

Who are Allogene Therapeutics' major shareholders?

Allogene Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include State Street Corp (5.49%), BlackRock Inc. (4.93%), Vanguard Group Inc. (4.70%), Primecap Management Co. CA (3.42%), JPMorgan Chase & Co. (2.48%) and Goldman Sachs Group Inc. (2.06%). Company insiders that own Allogene Therapeutics stock include Alison Moore, Arie Belldegrun, David D Chang, Eric Thomas Schmidt, Group Holdings (Sbs) Advis Tpg, Owen N Witte, Owen N Witte, Rafael Amado and Veer Bhavnagri.
View institutional ownership trends for Allogene Therapeutics

Which major investors are selling Allogene Therapeutics stock?

ALLO stock was sold by a variety of institutional investors in the last quarter, including Capital International Investors, Citigroup Inc., Duality Advisers LP, Panagora Asset Management Inc., Woodline Partners LP, JPMorgan Chase & Co., Group One Trading L.P., and Maven Securities LTD. Company insiders that have sold Allogene Therapeutics company stock in the last year include Alison Moore, David D Chang, Eric Thomas Schmidt, Owen N Witte, Rafael Amado, and Veer Bhavnagri.
View insider buying and selling activity for Allogene Therapeutics
or view top insider-selling stocks.

Which major investors are buying Allogene Therapeutics stock?

ALLO stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Goldman Sachs Group Inc., Renaissance Technologies LLC, BlackRock Inc., Pier Capital LLC, Nordea Investment Management AB, Primecap Management Co. CA, and Graham Capital Management L.P..
View insider buying and selling activity for Allogene Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Allogene Therapeutics?

Shares of ALLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Allogene Therapeutics' stock price today?

One share of ALLO stock can currently be purchased for approximately $7.48.

How much money does Allogene Therapeutics make?

Allogene Therapeutics has a market capitalization of $1.07 billion and generates $38.49 million in revenue each year. The company earns $-257.01 million in net income (profit) each year or ($2.200010) on an earnings per share basis.

How many employees does Allogene Therapeutics have?

Allogene Therapeutics employs 308 workers across the globe.

What is Allogene Therapeutics' official website?

The official website for Allogene Therapeutics is www.allogene.com.

How can I contact Allogene Therapeutics?

Allogene Therapeutics' mailing address is 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at (650) 457-2700 or via email at [email protected].

This page was last updated on 5/22/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.